

Definitive Results. Concise Reporting.

▶ **Genitourinary Histology**

- Prostate
 - ProstaVysion™
 - Decipher®
 - Oncotype DX®
 - ConfirmMDx®
- Immunohistochemistry (IHC)
 - QuadVysion™
- Bladder
 - BladderVysion™
- Renal
- Ureter
- Vas Deferens

▶ **Genitourinary Cytology**

- Cytology – Urine
- Cytology PRO™
- MicroVysion®
- RenalVysion
- UroVysion – Urine FISH

BOSTWICK LABORATORIES
100 Charles Lindbergh Blvd., Uniondale, NY 11553
Phone: 888-512-5288 Fax: 516-512-5301 www.bostwicklaboratories.com

SPECIMEN INFORMATION
BL15-0105-9999998
Date Collected: 09/12/2017
Date Received: 09/13/2017
Date Reported: 09/14/2017


PATIENT INFORMATION
Name: John D. Doe
SSN: XXX-XX-6789 Sex: Male
Date of Birth: 08/13/1959 Age: 58
Requisition #: 1234576 Chart #: 12345
Phone: (555) 456-7890

PHYSICIAN INFORMATION
John M. Jones
ABC Urology
123 Anywhere Street
Anywhere, VA 23226
Phone: (804) 555-1234
Fax: (804) 555-1235

Provided ICD-10 codes: R97.2. Previous Biopsy: None.


GROSS DESCRIPTION	
Site	Length
(A1) Right Apex	2.3 cm (Bisected - Green)
(C1) Right Base	1.9 cm (Black)
(E1) Right Lat Mid	2.2 cm (Bisected - No Ink)
(G1) Left Apex	2.3 cm (Bisected - Green)
(I1) Left Base	2.1 cm (Bisected - Black)
(K1) Left Lat Mid	1.9 cm (No Ink)

PHOTOMICROGRAPH



F1, ADENOCARCINOMA, Right Lat Base

PROSTATE BIOPSY MAP



DIAGNOSIS

A1 Right Apex:	Benign prostatic tissue.
B1 Right Lat Apex:	Benign prostatic tissue.
C1 Right Mid:	Benign prostatic tissue.
D1 Right Lat Mid:	Benign prostatic tissue.
E1 Right Base:	Benign prostatic tissue.
F1 Right Lat Base:	ADENOCARCINOMA (GLEASON SCORE 3 + 3 = 6) INVOLVING 15% OF THE SPECIMEN (1 OF 1 CORES CONTAIN CANCER).
G1 Left Apex:	Benign prostatic tissue.
H1 Left Lat Apex:	Benign prostatic tissue.
I1 Left Mid:	Benign prostatic tissue.
J1 Left Lat Mid:	Benign prostatic tissue.
K1 Left Base:	ADENOCARCINOMA (GLEASON SCORE 3 + 3 = 6) INVOLVING 15% OF THE SPECIMEN (1 OF 1 CORES CONTAIN CANCER).
L1 Left Lat Base:	Benign prostatic tissue.

Hillel Kahane, M.D.



**Absolute confidence
begins with choosing
the right laboratory**

▶ **Expertise** ▶ **Exceptional Service** ▶ **Innovation**

- Now part of Poplar Healthcare
- 24-48 hour TAT on most specimens
- Expanded insurance coverage
- Veteran pathologists
- Experienced specialty specific reps, and customer service team
- Ease of ordering prognostic testing platforms that improve the level of patient care

Bostwick Laboratories, a division of Poplar Healthcare, is a uropathology laboratory dedicated to the diagnosis, treatment, and management of prostate cancer, kidney disease, and cancer of the bladder. Bostwick Laboratories delivers highly specialized pathology service that is based on expertise, exceptional service and decades of innovation.

Innovation



Exceptional Service



▶ PROGNOSTIC TESTING

ProstaVysion™

ProstaVysion looks at two key biomarkers shown by research to alter prostate cancer cell growth, which may influence cancer risk assessment. Both markers provide useful, actionable and cost-effective prognosis information:

- Determines which patients may be candidates for active surveillance and which ones may need a more aggressive treatment
- For Gleason 6&7 prostate biopsies
- Identifies ERG gene fusion/translocation and the loss of the PTEN tumor suppressor gene

Decipher®

Decipher helps determine which patients are candidates for active surveillance, which may have excellent outcomes when treated with local therapy alone, and which patients may benefit from intensified treatment with multi-modal therapy.

- Indicated for the following NCCN risk groups: very low, low, favorable intermediate, and unfavorable intermediate
- Test results are reported independently of clinical and pathology features
- Superior independent accuracy: 5 year metastasis AUC = .87¹
- Testing platform is the whole genome microarray technology

Oncotype DX®

The Oncotype DX GPS is the only genomic test that was designed specifically for use in men with clinically low risk cancer (GS 3+3 or 3+4) who are deciding between active surveillance or treatment.

- The test predicts the likelihood of Prostate Cancer Death and Metastasis within 10 years after RP, and Adverse Pathology* using multiple genomic pathways.
- OncotypeDX Genomic Prostate Score (GPS) report provides precise clinical risk and pathology information to guide patient discussions and treatment decisions.

BladderVysion™

Provides a prognostic analysis for the risk of bladder cancer progression

- The prognostic grade summarizes the risk of progression
- The panel uses markers indicative of low-grade or high-grade carcinoma
- FGFR3, p53, Ki-67, and PTEN

▶ URINE MICROBIOME AND ANTIBIOTIC RESISTANCE ASSAY

Comprehensive Next Generation DNA Sequencing assay that detects more bacteria, parasites, fungi, and targeted viruses than traditional cultures alone.

- **ProstaSeq** – for patients with culture negative prostatitis
- **UroSeq** - for patients with interstitial cystitis, recurrent UTI, and urinary infectious syndromes

Both tests also provide actionable data on pathogen load and drug resistance genes

▶ CONFIRMATORY TEST

ConfirmMDx®

The ConfirmMDx for Prostate Cancer testing solution addresses false-negative biopsy concerns, helping urologists:

- “Rule-out” otherwise cancer-free men from undergoing unnecessary repeat biopsies and screening procedures
- “Rule-in” high-risk men with a previous negative biopsy result who may be harboring undetected cancer (false-negative biopsy result) and therefore may benefit from a repeat biopsy and potentially treatment

For men with an initial negative biopsy, independently published clinical studies have shown that the ConfirmMDx® test is the most significant, independent predictor of patient outcome relative to other available clinical factors such as age, PSA and DRE results^{2,3}

▶ HEMATURIA TEST

MicroVysion™

Noninvasive urine test focused on the origin of hematuria. It separates upper tract (kidney) bleeding from the lower tract (ureters, bladder, urethra)

It combines:

- Urine cytology with Papanicolaou (Pap) and acid hematoxylin (or Feulgen) stains for urine cytology. This improves the visualization of nuclear abnormalities in single urothelial cells and particularly those in three dimensional clusters
- Microscopy is used in the diagnosis of infections, inflammatory conditions, diseases of the kidney and a wide variety of systemic or chronic disease such as diabetes, hypertension and immune processes such as lupus
- Special chemistry is used to determine kidney health

▶ CONNECT

Order: *WebLynx*

- Create requisitions accurately and quickly
- Linked to your practice management's patient information

EMR Interface

- Interfacing with most of the leading EMR companies
- Data distributed in both HL-7 format and picture file format (PDF)

Deliver:

- EMR
- Web based reporting
- Auto print
- On demand access to the Summary Report and Patient Education, through Webdox, the secure web portal

▶ INNOVATIVE TC PC OPTIONS

Create reports in our user friendly Laboratory Information System

- Assistance with your Quality Management requirements

▶ PATIENT SUMMARY REPORT

Patient summary report is available for patients who have had more than one test performed with a clinician. This report complements the historical reports and can be used as a dashboard to track the medical history of the patient.

- Tests included in the summary report include: Prostate Histology, ProstaVysion, Cytology tests, MicroVysion, FISH, Bladder Histology, and BladderVysion

▶ PATIENT EDUCATION

Patient education is available for our prostate histology, ProstaVysion, and BladderVysion tests. These pages accompany the report and can be used by the physician to help the patient understand their diagnosis and comprehend the next steps for treatment or surveillance.

- Optional item for physicians

ProstaVysion, BladderVysion, MicroVysion is a trademarks of Poplar Healthcare

Decipher is a trademark of GenomeDx Biosciences Inc.

Oncotype Dx is a registered trademark of Genomic Health, Inc.

ConfirmMDx is a registered trademark of MDx Health, SA.

¹ Klein et al., *Urology*, 2016

² Van Nest et al., *Risk Score Predicts High-Grade Prostate Cancer in DNA-Methylation Positive, Histopathologically Negative Biopsies. The Prostate* 2016

³ Partin et al., *Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Biopsies. Journal of Urology* 2014. doi.org/10.106/j.juro.2014.04.13

**BOSTWICK
LABORATORIES®**
A DIVISION OF POPLAR HEALTHCARE